Healthcare • Biotechnology
EODHD (TTM) · as of Oct 13, 2026
End-of-day close from stored market data, not a live quote.
Sign in to see your position size
We’ll show you if EXEL is in your portfolio and how much it contributes.
Sign inLoading market dates
No upcoming ex-dividend date announced
No 8-K filings in the last 30 days.
93 top institutions tracked
Last 13F trend: unchanged (light)
Unlock crowding heatmapUnlock filer discoverySentiment: neutral
Last trade: sell 63 days ago
Red flags: 1
760 filers reported a long position in EXEL for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
| Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|
| BlackRock, Inc. | $1.6B | 29.1M | -5.6% |
| FARALLON CAPITAL MANAGEMENT, L.L.C. | $732.8M | 13.5M | +2.7% |
| RENAISSANCE TECHNOLOGIES LLC | $730.6M | 13.4M | -2.2% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $655.3M | 12M | -0.3% |
| AQR CAPITAL MANAGEMENT LLC | $598.6M | 11M | -15.8% |
| VANGUARD CAPITAL MANAGEMENT LLC | $595.8M | 11M | -2.7% |
| STATE STREET CORP | $542.5M | 10M | -3.2% |
| FULLER & THALER ASSET MANAGEMENT, INC. | $485.8M | 8.9M | +4.5% |
| LSV ASSET MANAGEMENT | $443.3M | 8.1M | +5.2% |
| GEODE CAPITAL MANAGEMENT, LLC | $416.3M | 7.7M | -1.9% |
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.